Phase I Study to Assess the Safety and Efficacy of OCU200 for Center-Involved Diabetic Macular Edema (DME) (NCT05802329)

🧪 Interventions in This Study

• OCU200 (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (5 Sites)

• Advanced Research LLC — Deerfield Beach, Florida
• Erie Retina Research, LLC — Erie, Pennsylvania
• Retina Consultants of Texas Research Centers — Bellaire, Texas
• Retina Consultants of America — Southlake, Texas
• Gundersen Health System — La Crosse, Wisconsin

📞 Contact the Study Coordinator

Phone: (845) 664-1505

Email: roshan.george@ocugen.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

Explore by condition: All Center Involved Diabetic Macular Edema clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.